
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About
Cibus Global LLC (CBUS)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/04/2025: CBUS (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -72.66% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 52.23M USD | Price to earnings Ratio - | 1Y Target Price 17.62 |
Price to earnings Ratio - | 1Y Target Price 17.62 | ||
Volume (30-day avg) 171035 | Beta 1.84 | 52 Weeks Range 1.50 - 21.23 | Updated Date 04/5/2025 |
52 Weeks Range 1.50 - 21.23 | Updated Date 04/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -10.83 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-03-19 | When After Market | Estimate -0.76 | Actual -0.87 |
Profitability
Profit Margin - | Operating Margin (TTM) -1487.13% |
Management Effectiveness
Return on Assets (TTM) -10.76% | Return on Equity (TTM) -129.65% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 71463384 | Price to Sales(TTM) 12.25 |
Enterprise Value 71463384 | Price to Sales(TTM) 12.25 | ||
Enterprise Value to Revenue 16.77 | Enterprise Value to EBITDA -1.15 | Shares Outstanding 32638400 | Shares Floating 24532662 |
Shares Outstanding 32638400 | Shares Floating 24532662 | ||
Percent Insiders 24.56 | Percent Institutions 29.07 |
Analyst Ratings
Rating 4.25 | Target Price 18.12 | Buy 1 | Strong Buy 2 |
Buy 1 | Strong Buy 2 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Cibus Global LLC
Company Overview
History and Background
Cibus Global LLC is a biotechnology company focused on gene editing to develop improved crop varieties. Founded in 2001, Cibus has focused on developing a proprietary Rapid Trait Development System (RTDS) gene editing technology. Key milestones include successful development of traits in various crops, partnerships with seed companies, and continued advancement of its technology platform.
Core Business Areas
- Trait Development: Developing and licensing novel plant traits using its RTDS technology. These traits are aimed at improving crop yield, disease resistance, and herbicide tolerance.
- Licensing and Partnerships: Licensing its RTDS technology and traits to seed companies and other agricultural organizations.
- Seed Production: Producing seeds with the traits developed to sell to farmers.
Leadership and Structure
The leadership team includes Peter Beetham (CEO). Cibus has a typical biotech structure with research, development, commercialization, and administrative departments.
Top Products and Market Share
Key Offerings
- Trait Developed for Canola: Cibus developed traits for herbicide tolerance for canola. Competitors include Bayer (BAYRY), Corteva (CTVA), and BASF in the herbicide-tolerant trait market. Data on market share is not publically available.
- Trait Developed for Rice: Cibus is working to provide traits for weed control on Rice that would give farmers increased flexibility with weed control. Competitors include Bayer (BAYRY), Corteva (CTVA), and BASF in the herbicide-tolerant trait market. Data on market share is not publically available.
Market Dynamics
Industry Overview
The agricultural biotechnology industry is driven by the need for improved crop yields, increased disease resistance, and more efficient farming practices. Gene editing technologies are a growing segment within this industry.
Positioning
Cibus is positioned as a technology provider, licensing its gene editing platform and traits to seed companies. Its competitive advantage lies in its RTDS technology, which it claims offers precision and efficiency in trait development.
Total Addressable Market (TAM)
The TAM for agricultural biotechnology is estimated to be over $50 billion. Cibus is positioned to capture a portion of this market by providing its RTDS technology and traits to seed companies, enabling them to develop and market improved crop varieties.
Upturn SWOT Analysis
Strengths
- Proprietary RTDS technology
- Experienced leadership team
- Partnerships with seed companies
- Potential for recurring revenue through licensing
Weaknesses
- Limited commercialized products
- Reliance on partnerships for revenue
- Regulatory hurdles for gene-edited crops
- Competition from established players
Opportunities
- Expanding RTDS technology to new crops
- Developing new traits to address emerging agricultural challenges
- Increasing adoption of gene-edited crops
- Entering new geographic markets
Threats
- Regulatory changes impacting gene editing
- Negative public perception of GMOs/gene-edited crops
- Competition from other gene editing technologies
- Economic downturn affecting agricultural investment
Competitors and Market Share
Key Competitors
- BAYRY
- CTVA
- BASF
Competitive Landscape
Cibus faces competition from established agricultural companies with significant resources and market presence. Its success depends on the superior performance and cost-effectiveness of its RTDS technology compared to existing methods.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is not publicly available due to Cibus being a private company.
Future Projections: Future projections are not publicly available due to Cibus being a private company, but growth is expected to come from continued advancements to the RTDS technology platform and more partnerships.
Recent Initiatives: Recent initiatives include expanding its RTDS platform, and expanding their canola traits.
Summary
Cibus Global LLC is a private biotechnology company innovating in gene editing for crop improvement using their RTDS technology. Cibus is striving to improve crop yields and enhance agricultural sustainability. The company's reliance on partnerships and regulatory hurdles pose potential challenges. Its continued advancement of the RTDS platform and expansion into new crops will determine its success.
Similar Companies

CTVA

Corteva Inc



CTVA

Corteva Inc

DD

Dupont De Nemours Inc



DD

Dupont De Nemours Inc
Sources and Disclaimers
Data Sources:
- Cibus Global LLC website
- Industry reports on agricultural biotechnology
- Publicly available competitor information
Disclaimers:
The information provided is based on publicly available data and may not be entirely accurate due to the private status of Cibus Global LLC. Market share data is estimated and may not reflect the exact figures.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cibus Global LLC
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2023-06-01 | Co-Founder, Interim CEO, President, COO & Director Dr. Peter R. Beetham B.Sc., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 157 | Website https://www.cibus.com |
Full time employees 157 | Website https://www.cibus.com |
Cibus, Inc., an agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. It focuses on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or linked to environmental challenges. Cibus, Inc. is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.